NovoEight (turoctocog alfa) is a protein pharmaceutical. Turoctocog alfa was first approved as NovoEight on 2013-11-13. It is used to treat factor VII deficiency, hemophilia a, hemorrhage, and von willebrand diseases in the USA. It has been approved in Europe to treat hemophilia a.
|Common Name||Turoctocog alfa|
|Indication||factor vii deficiency, hemophilia a, hemorrhage, von willebrand diseases|